|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_ocn994006049 |
| 003 |
OCoLC |
| 005 |
20231120010208.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170718t20172017enk ob 001 0 eng d |
| 010 |
|
|
|a 2017939024
|
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d IDEBK
|d EBLCP
|d N$T
|d UIU
|d OPELS
|d OCLCQ
|d GZM
|d UPM
|d YDX
|d MERER
|d OCLCQ
|d NRC
|d COO
|d D6H
|d DKU
|d U3W
|d OCLCF
|d MERUC
|d AU@
|d CASUM
|d OCLCQ
|d WYU
|d OCLCA
|d OCLCQ
|d OCLCO
|d S2H
|d OCLCO
|d VT2
|d OCLCA
|d OCLCO
|d OCLCQ
|d SFB
|d OCLCO
|
| 016 |
7 |
|
|a 101713757
|2 DNLM
|
| 019 |
|
|
|a 994128255
|a 1010742725
|a 1066658314
|a 1162218131
|a 1235830593
|
| 020 |
|
|
|a 9780128038000
|q (electronic bk.)
|
| 020 |
|
|
|a 0128038004
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128037966
|
| 020 |
|
|
|z 0128037962
|
| 035 |
|
|
|a (OCoLC)994006049
|z (OCoLC)994128255
|z (OCoLC)1010742725
|z (OCoLC)1066658314
|z (OCoLC)1162218131
|z (OCoLC)1235830593
|
| 050 |
|
4 |
|a RM315
|
| 060 |
|
4 |
|a 2017 H-155
|
| 060 |
|
4 |
|a WL 200
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7/8
|2 23
|
| 100 |
1 |
|
|a �Ozdemir, Yasemin G�ursoy,
|e author.
|
| 245 |
1 |
0 |
|a Nanotechnology methods for neurological diseases and brain tumors :
|b drug delivery across the blood--brain barrier /
|c Yasemin G�ursoy-�Ozdemir, Sibel Bozda�g-Pehlivan, Emine Sekerdag.
|
| 264 |
|
1 |
|a London :
|b Academic Press,
|c [2017]
|
| 264 |
|
4 |
|c �2017
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Vendor-supplied metadata.
|
| 505 |
0 |
|
|a Cover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- About the Editors -- Preface -- References -- Part 1 -- The Rationale to Reach the Brain -- Chapter 1 -- Anatomy and Physiology of the Blood-Brain Barrier -- 1 -- Introduction -- 2 -- Structure of the BBB -- 3 -- BBB Developmental Steps -- 4 -- Transport Across the BBB -- 4.1 -- Passive Transfer or Diffusion -- 4.2 -- Solute Carrier System -- 4.3 -- ATP-Binding Transporters of Efflux Transporters -- 4.4 -- Transport of Macromolecules -- 5 -- Conclusions -- Abbreviations -- References -- Chapter 2 -- Blood-Brain Barrier: Genomics, Proteomics, Disease Targets, and Drug Delivery -- 1 -- Introduction -- 2 -- Blood-Brain Barrier Genomics -- 2.1 -- Genome Products Selectively Expressed at the BBB -- 2.2 -- Methods Used in BBB Genomics -- 3 -- Blood-Brain Barrier Proteomics -- 4 -- Disease Targets -- 5 -- Drug Delivery -- 5.1 -- Recombinant Proteins and Monoclonal Antibodies -- 5.2 -- Gene-Based Systems -- 6 -- Conclusions -- Abbreviations -- References -- Chapter 3 -- Brain and the Drug Transporters -- 1 -- Introduction -- 2 -- Brain Transporters -- 2.1 -- ABC Drug Transporters -- 2.1.1 -- ABCB1: P-Glycoprotein -- 2.1.2 -- ABCC: Multidrug Resistance-Associated Protein -- 2.1.3 -- ABCG2: Breast Cancer Resistance Protein -- 2.2 -- SLC Transporters -- 2.2.1 -- SLCO1: Organic Anion Transporting Polypeptides -- 2.2.2 -- SLC22A6-8: Organic Anion Transporters -- 2.2.3 -- SLC22A: Organic Cation Transporters -- 2.2.4 -- SLC16A: Monocarboxylate Transporters -- 2.2.5 -- SLC15A: Oligopeptide Transporters -- 2.2.6 -- Nucleoside Transporters -- 3 -- Conclusions -- Abbreviations -- References -- Chapter 4 -- Drug Delivery to the Brain: Pharmacokinetic Concepts -- 1 -- Introduction -- 2 -- CNS Drug Delivery -- 2.1 -- Barriers to CNS Drug Delivery -- 2.2 -- BBB Transport Mechanism -- 2.2.1 -- Passive Diffusion -- 2.2.2 -- Endocytosis.
|
| 505 |
8 |
|
|a 2.2.3 -- Active Transport -- 2.3 -- Rate of Drug Delivery to the Brain -- 2.4 -- Extent of Drug Delivery to the Brain -- 3 -- Intrabrain Distribution -- 4 -- Conclusions -- Abbreviations -- References -- Part 2 -- Nose-to-Brain Drug Delivery -- Chapter 5 -- Nasal Physiology and Drug Transport -- 1 -- Introduction -- 2 -- Anatomy of the Nose -- 3 -- Nasal Transport Mechanisms -- 3.1 -- Mucus Layer -- 3.2 -- Olfactory Pathway -- 3.3 -- Trigeminal Pathway -- 4 -- Factors Affecting Nose-to-Brain Transport -- 5 -- Principles of Drug Administration -- 6 -- Conclusions -- Abbreviations -- References -- Chapter 6 -- Challenges of the Nose-to-Brain Route -- 1 -- Introduction -- 2 -- Nose-to-Brain Research -- 3 -- Overcoming Barriers in Nasal Drug Delivery -- 3.1 -- Physiological Possibilities -- 3.2 -- Surface Modifications of Drugs -- 3.3 -- Nanoparticle Formulations -- 4 -- In Vitro and In Vivo Models for Nasal Drug Delivery -- 5 -- Conclusions -- Abbreviations -- References -- Part 3 -- Nanoscience in Targeted Brain Drug Delivery -- Chapter 7 -- Nanoscience in Targeted Brain Drug Delivery -- 1 -- Importance and Application of Nanotechnology-Based Brain Drug Delivery Systems -- 1.1 -- Nanoparticles -- 1.1.1 -- Metallic Nanoparticles -- 1.1.2 -- Silica Nanoparticles -- 1.1.3 -- Polymeric Nanoparticles -- 1.1.4 -- Lipid Nanoparticles -- 1.2 -- Liposomes -- 1.3 -- Dendrimers -- 1.4 -- Polymeric Micelles -- 1.5 -- Carbon Nanotubes -- 2 -- Neurotoxicity -- 3 -- Clinical Considerations -- 4 -- Ethical and Regulatory Issues -- 5 -- Conclusions -- Abbreviations -- References -- Part 4 -- Brain-Targeted Experimental Models -- Chapter 8 -- In Vitro CNS Models -- 1 -- Introduction -- 1.1 -- Development of In Vitro Cell Culture Models -- 2 -- Cellular Structure of the BBB -- 3 -- Tight Junctions and In Vitro Paracellular Barrier Characterization -- 4 -- Cell Culture Models.
|
| 505 |
8 |
|
|a 4.1 -- 2D In Vitro BBB Models: Monoculture and Coculture -- 4.1.1 -- Noncerebral-Based In Vitro Cell Culture Models -- 4.1.2 -- Cerebral-Based In Vitro Cell Culture Models -- 4.1.2.1 -- Primary Brain Endothelial Cell Culture -- 4.1.2.2 -- Immortalized Cell Lines -- 4.1.3 -- BBB Models of Cocultures -- 4.1.3.1 -- Coculture of Endothelial Cells With Astrocytes -- 4.1.3.2 -- Coculture of Endothelial Cells With Pericytes -- 4.1.3.3 -- Coculture of Endothelial Cells With Neurons and Microglia -- 4.1.3.4 -- Coculture of Stem Cells/Stem Cell-Derived Cells -- 4.2 -- 3D In Vitro BBB Models -- 4.3 -- Dynamic Models of the BBB -- 4.4 -- Microfluidic BBB Models -- 4.5 -- Disease Models -- 5 -- Comparison of In Vitro Cell Culture Models -- 6 -- Conclusions and Future Outlook -- Abbreviations -- References -- Chapter 9 -- In Vivo/In Situ Animal Models -- 1 -- Introduction -- 2 -- Animal Models of Alzheimer's Disease -- 3 -- Animal Models of Parkinson's Disease -- 4 -- Animal Models of Huntington's Disease -- 5 -- Animal Models of Depression -- 6 -- Animal Models of Anxiety -- 7 -- Animal Models of Schizophrenia -- 8 -- Animal Models of Pain -- 9 -- Animal Models of Stroke -- 10 -- Animal Models of Brain Tumor -- 11 -- Conclusions -- Abbreviations -- References -- Chapter 10 -- Microdialysis and Brain Perfusion -- 1 -- Introduction -- 2 -- Techniques in Relation to Measured Entities -- 3 -- Microdialysis -- 3.1 -- Aspects of Microdialysis in Relation to NC Studies -- 3.2 -- Methodological Aspects -- 3.2.1 -- In Vitro Preparations -- 3.2.2 -- In Vivo Preparations -- 3.3 -- Microdialysis Study Design of Nanodelivery to the Brain -- 4 -- Open Flow Microperfusion -- 5 -- In Situ Brain Perfusion -- 6 -- Discussion -- Abbreviations -- References -- Chapter 11 -- Neuroimaging: Techniques and General Applications -- 1 -- Introduction -- 2 -- Ultrasonography -- 3 -- Computed Tomography.
|
| 505 |
8 |
|
|a 6 -- Tolerance Induction -- 7 -- Neuroprotection -- 8 -- Nanotechnology in Nonautoimmune Neuroinflammation -- 9 -- Neuroinflammatory Adverse Effects of Nanoparticles -- 10 -- Concluding Remarks -- Abbreviations -- References -- Chapter 16 -- Infectious Diseases of the Brain -- 1 -- Introduction -- 2 -- Brain Infections -- 2.1 -- Meningitis -- 2.1.1 -- Bacterial Meningitis -- 2.1.1.1 -- Etiology of Bacterial Meningitis -- 2.1.1.2 -- Treatment -- 2.1.1.3 -- Novel Antibiotics -- 2.1.1.3.1 -- Cefepime -- 2.1.1.3.2 -- Meropenem -- 2.1.1.3.3 -- Daptomycin -- 2.1.1.3.4 -- Televancin -- 2.1.1.4 -- New Treatment Options -- 2.1.1.4.1 -- Adjunctive Treatment With Corticosteroid -- 2.1.1.4.2 -- Nonbacteriolytic Antibiotics -- 2.1.1.4.3 -- Vaccines -- 2.1.2 -- Viral Meningitis -- 2.1.2.1 -- Treatment -- 2.2 -- Encephalitis -- 2.2.1 -- Etiology of Encephalitis -- 2.3 -- Brain Abscesses -- 2.3.1 -- Etiology of Brain Abscess -- 2.3.2 -- Treatment -- 3 -- Consideration of the Treatment of Brain Infections -- 3.1 -- Lack of Information on Microbial Translocation into the CNS -- 3.2 -- BBB and BCSFB -- 3.3 -- Antibiotic Resistance -- 4 -- Nanotechnological Approach and Recent Trends in Brain Infection Treatments -- 4.1 -- Polymeric Nanoparticles -- 4.2 -- Polymeric Micelles -- 4.3 -- Solid Lipid Nanoparticles -- 4.4 -- Cationic Antimicrobial Peptides -- 4.5 -- Liposomes -- 4.6 -- Cell-Mediated Drug Delivery -- 5 -- Conclusions -- Abbreviations -- References -- Part 6 -- Brain Tumors -- Chapter 17 -- Brain Tumors -- 1 -- Introduction -- 2 -- Types of Brain Tumors -- 2.1 -- Tumor Cell Kinetics -- 3 -- Conventional Treatment Approaches -- 3.1 -- Surgery -- 3.2 -- Radiation Therapy -- 3.3 -- Chemotherapy -- 4 -- Blood-Brain Tumor Barrier -- 5 -- Overcoming the BBB -- 5.1 -- Drug Modification -- 5.2 -- Reversible Opening of the BBB -- 5.3 -- Implantation of Drug Delivery Systems.
|
| 505 |
8 |
|
|a 6 -- Nanotechnology-Based Drug Delivery Systems.
|
| 650 |
|
0 |
|a Blood-brain barrier
|x Effect of drugs on.
|
| 650 |
|
0 |
|a Blood-brain barrier
|x Metabolism.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
0 |
|a Nanotechnology.
|
| 650 |
1 |
2 |
|a Blood-Brain Barrier
|x metabolism
|0 (DNLM)D001812Q000378
|
| 650 |
2 |
2 |
|a Central Nervous System Agents
|x pharmacokinetics
|0 (DNLM)D002491Q000493
|
| 650 |
2 |
2 |
|a Central Nervous System Diseases
|x drug therapy
|0 (DNLM)D002493Q000188
|
| 650 |
2 |
2 |
|a Blood-Brain Barrier
|x drug effects
|0 (DNLM)D001812Q000187
|
| 650 |
2 |
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
2 |
2 |
|a Nanomedicine
|x methods
|0 (DNLM)D050997Q000379
|
| 650 |
|
2 |
|a Nanotechnology
|0 (DNLM)D036103
|
| 650 |
|
6 |
|a Barri�ere h�emato-enc�ephalique
|0 (CaQQLa)201-0006101
|x Effets des m�edicaments sur.
|0 (CaQQLa)000273919
|
| 650 |
|
6 |
|a Barri�ere h�emato-enc�ephalique
|0 (CaQQLa)201-0006101
|x M�etabolisme.
|0 (CaQQLa)201-0379985
|
| 650 |
|
6 |
|a M�edicaments
|x D�eveloppement.
|0 (CaQQLa)201-0306620
|
| 650 |
|
6 |
|a Nanotechnologie.
|0 (CaQQLa)201-0225435
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Drug development
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Nanotechnology
|2 fast
|0 (OCoLC)fst01032639
|
| 655 |
|
0 |
|a Electronic books.
|
| 655 |
|
4 |
|a Internet Resources.
|
| 700 |
1 |
|
|a Pehlivan, Sibel Bozdag,
|e author.
|
| 700 |
1 |
|
|a Sekerdag, Emine,
|e author.
|
| 776 |
0 |
8 |
|i Print version:
|a �Ozdemir, Yasemin G�ursoy.
|t Nanotechnology methods for neurological diseases and brain tumors.
|d London : Academic Press, [2017]
|z 0128037962
|z 9780128037966
|w (OCoLC)974025362
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128037966
|z Texto completo
|
